Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Summary

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving everolimus together with lenalidomide may be an effective treatment for lymphoma.

PURPOSE: This phase I/II trial is studying the side effects and best dose of giving everolimus and lenalidomide together and to see how well they work in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma.

Conditions

• Adult Nasal Type Extranodal NK/T-cell Lymphoma
• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Hepatosplenic T-cell Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Peripheral T-cell Lymphoma
• Post-transplant Lymphoproliferative Disorder
• Recurrent Adult Burkitt Lymphoma
• Recurrent Adult Diffuse Large Cell Lymphoma
• Recurrent Adult Hodgkin Lymphoma
• Recurrent Adult T-cell Leukemia/Lymphoma
• Recurrent Grade 1 Follicular Lymphoma
• Recurrent Grade 2 Follicular Lymphoma
• Recurrent Grade 3 Follicular Lymphoma
• Recurrent Mantle Cell Lymphoma
• Recurrent Mycosis Fungoides/Sezary Syndrome
• Splenic Marginal Zone Lymphoma
• Waldenstrom Macroglobulinemia

Interventions

DRUG

everolimus

Given orally

DRUG

lenalidomide

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

polymorphism analysis

Correlative studies

OTHER

immunohistochemistry staining method

Optional correlative studies

GENETIC

microarray analysis

Optional correlative studies

GENETIC

fluorescence in situ hybridization

Optional correlative studies

Sponsors & Collaborators

• Mayo Clinic

  lead OTHER

Principal Investigators

• Craig Reeder, M.D. · Mayo Clinic

• Thomas E. Witzig, M.D. · Mayo Clinic

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-01-10

Primary Completion

2015-02-28

Completion

2020-02-13

Countries

• United States

Study Locations